Jardiance® (empagliflozin) – New indication
September 22, 2023 - Eli Lilly announced the FDA approval of Jardiance (empagliflozin), to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
Top